Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesPhenotype and Genotype-Infectious AgentsCPT cpt-87913-sars-cov-2-genotype-analysis-next-generation-sequencing
    Ask Trek AI about this page

    CPT 87913: SARS–CoV–2 Genotype Analysis by Next‑Generation Sequencing

    CPT code 87913 describes genotype analysis for patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection using next-generation sequencing to identify viral mutations that may affect transmissibility or disease severity; the service is a molecular diagnostic genotyping/sequencing test typically performed in a clinical laboratory or reference laboratory setting on a patient respiratory specimen.

    For related coverage guidance, see recent payer policy updates: Biomarker Testing for Autoimmune Rheumatic Disease, Immunopharmacologic Monitoring of Therapeutic Serum Antibodies, Immune Cell Function Assay.

    Customize your policy alerts

    Sign up for cpt 87913 policy alerts

    Get alerted when payer policies referencing 87913 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A patient with confirmed SARS–CoV–2 infection (positive RT-PCR) is admitted to an acute care hospital for progressive respiratory symptoms and concern for a new variant with increased transmissibility. A nasopharyngeal swab or lower respiratory specimen already collected for diagnostic testing is sent to the hospital molecular laboratory or a reference molecular pathology laboratory for genotype analysis using next‑generation sequencing. The clinical workflow: specimen accessioning and verification, nucleic acid extraction, library preparation, next‑generation sequencing targeted to the viral genome, bioinformatic variant calling and annotation, and a clinically focused report noting mutations of interest (for example, spike protein substitutions) that could affect transmissibility or disease severity. Results are communicated to the ordering infectious disease physician or hospital epidemiology team to inform infection control, public health reporting, and potential antiviral selection considerations.

    Related Diagnoses

    ICD-10 CodeDescriptionClinical Relevance
    U07.1COVID-19Primary diagnosis for confirmed SARS–CoV‑2 infection; indicates clinical context for genotype analysis.
    J12.82Pneumonia due to coronavirus disease 2019Indicates lower respiratory involvement where variant identification may impact clinical management.
    J96.00Acute respiratory failure, unspecified whether with hypoxia or hypercapniaSevere respiratory compromise prompting advanced molecular analysis to assess variant-related severity.
    B97.29Other coronavirus as the cause of diseases classified elsewhereAlternate diagnosis code used in some contexts for coronavirus infections when detailed coding required.
    Z20.822Contact with and (suspected) exposure to COVID-19Epidemiologic relevance when tracing exposures and variant spread; supports public health reporting.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    2080P0207X
    163W00000X
    111NR0400X
    133VN1401X
    207VM0101X
    163WH0500X
    163WD1100X

    Related Payer Policy Updates

    Specialty: Immunology/Rheumatology1 / 3

    10 rows

    PolicyPayerEffective Date
    Biomarker Testing for Autoimmune Rheumatic DiseaseOscar Health2026-10-01
    Immunopharmacologic Monitoring of Therapeutic Serum AntibodiesOscar Health2026-10-01
    Immune Cell Function AssayOscar Health2026-10-01
    Biomarker Testing for Autoimmune Rheumatic DiseaseBlue Cross Blue Shield - New Mexico2026-09-04
    Inflammatory Conditions - Orencia Intravenous Preferred Specialty Management Policy for Legacy Prescription Drug ListsCigna2026-09-01
    Secukinumab (Cosentyx) — intravenous (Medicare Advantage)blue cross blue shield - louisiana2026-09-01
    Intravenous Immune Globulin (IVIG) — indications and authorization criteriaBlue Cross Blue Shield - Iowa2026-08-28
    Infliximab Intravenous Products Preferred Specialty Management PolicyCigna2026-08-15
    Kineret (anakinra) — Coverage CriteriaBlue Cross Blue Shield - Iowa2026-08-14
    Actimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteriameridian_health_plan_of_michigan2026-08-01

    Related Codes

    CPT-87900-VIRAL-DRUG-SUSCEPTIBILITY-GENOTYPIC-PHENOTYPE-PREDICTION

    CPT 87900: Viral Drug Susceptibility and Phenotype Prediction

    CPT-87901-HIV-1-GENOTYPE-REVERSE-TRANSCRIPTASE-PROTEASE-ANALYSIS

    CPT 87901: HIV‑1 Genotype — Protease and Reverse Transcriptase Sequencing

    CPT-87902-HEPATITIS-C-GENOTYPE-NUCLEIC-ACID-TESTING-TECHNICAL

    CPT 87902: Hepatitis C Virus Genotype by Nucleic Acid Analysis

    CPT-87903-HIV-1-DRUG-RESISTANCE-NUCLEIC-ACID-ANALYSIS

    CPT 87903: HIV-1 Drug Resistance Testing, Culture-Based

    CPT-87904-HIV-1-DRUG-RESISTANCE-ADDITIONAL-DRUG-TESTING

    CPT 87904: HIV‑1 Drug Resistance Test, Additional Drug

    CPT-87905-ENZYMATIC-ACTIVITY-TESTING-INFECTIOUS-AGENT-TECHNICAL

    CPT 87905: Enzymatic Activity Test for Non-Viral Infectious Agents

    CPT-87906-HIV-1-GENOTYPE-NUCLEIC-ACID-NON-RT-PROTEASE-REGIONS

    CPT 87906: HIV‑1 Genotype by Nucleic Acid (non-RT/protease)

    CPT-87910-CMV-GENOTYPE-NUCLEIC-ACID-ANALYSIS

    CPT 87910: CMV Genotype Analysis by Nucleic Acid Testing

    CPT-87912-HEPATITIS-B-GENOTYPE-ANALYSIS-NUCLEIC-ACID

    CPT 87912: Hepatitis B Virus Genotype Analysis

    CPT-87999-UNLISTED-MICROBIOLOGY-PROCEDURE

    CPT 87999: Unlisted Microbiology Procedure

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.